These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 19103992)

  • 1. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure.
    Rengo G; Lymperopoulos A; Zincarelli C; Donniacuo M; Soltys S; Rabinowitz JE; Koch WJ
    Circulation; 2009 Jan; 119(1):89-98. PubMed ID: 19103992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model.
    Raake PW; Schlegel P; Ksienzyk J; Reinkober J; Barthelmes J; Schinkel S; Pleger S; Mier W; Haberkorn U; Koch WJ; Katus HA; Most P; Müller OJ
    Eur Heart J; 2013 May; 34(19):1437-47. PubMed ID: 22261894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition.
    Völkers M; Weidenhammer C; Herzog N; Qiu G; Spaich K; Wegner FV; Peppel K; Müller OJ; Schinkel S; Rabinowitz JE; Hippe HJ; Brinks H; Katus HA; Koch WJ; Eckhart AD; Friedrich O; Most P
    Circ Res; 2011 Jan; 108(1):27-39. PubMed ID: 21106943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV6-βARKct gene delivery mediated by molecular cardiac surgery with recirculating delivery (MCARD) in sheep results in robust gene expression and increased adrenergic reserve.
    Katz MG; Fargnoli AS; Swain JD; Tomasulo CE; Ciccarelli M; Huang ZM; Rabinowitz JE; Bridges CR
    J Thorac Cardiovasc Surg; 2012 Mar; 143(3):720-726.e3. PubMed ID: 22143102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Right ventricular beneficial effects of beta adrenergic receptor kinase inhibitor (betaARKct) gene transfer in a rat model of severe pressure overload.
    Molina EJ; Gupta D; Palma J; Gaughan JP; Macha M
    Biomed Pharmacother; 2009 Jun; 63(5):331-6. PubMed ID: 18801641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute ischemic cardiac dysfunction is attenuated via gene transfer of a peptide inhibitor of the beta-adrenergic receptor kinase (betaARK1).
    Tevaearai HT; Walton GB; Keys JR; Koch WJ; Eckhart AD
    J Gene Med; 2005 Sep; 7(9):1172-7. PubMed ID: 15880449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure.
    Tachibana H; Naga Prasad SV; Lefkowitz RJ; Koch WJ; Rockman HA
    Circulation; 2005 Feb; 111(5):591-7. PubMed ID: 15668342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCARD-mediated gene transfer of GRK2 inhibitor in ovine model of acute myocardial infarction.
    Swain JD; Fargnoli AS; Katz MG; Tomasulo CE; Sumaroka M; Richardville KC; Koch WJ; Rabinowitz JE; Bridges CR
    J Cardiovasc Transl Res; 2013 Apr; 6(2):253-62. PubMed ID: 23208013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms.
    Bathgate-Siryk A; Dabul S; Pandya K; Walklett K; Rengo G; Cannavo A; De Lucia C; Liccardo D; Gao E; Leosco D; Koch WJ; Lymperopoulos A
    Hypertension; 2014 Feb; 63(2):404-12. PubMed ID: 24218435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Various effects of AAV9-mediated βARKct gene therapy on the heart in dystrophin-deficient (mdx) mice and δ-sarcoglycan-deficient (Sgcd-/-) mice.
    Bauer R; Enns H; Jungmann A; Leuchs B; Volz C; Schinkel S; Koch WJ; Raake PW; Most P; Katus HA; Müller OJ
    Neuromuscul Disord; 2019 Mar; 29(3):231-241. PubMed ID: 30782477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GRK2 blockade with βARKct is essential for cardiac β2-adrenergic receptor signaling towards increased contractility.
    Salazar NC; Vallejos X; Siryk A; Rengo G; Cannavo A; Liccardo D; De Lucia C; Gao E; Leosco D; Koch WJ; Lymperopoulos A
    Cell Commun Signal; 2013 Aug; 11():64. PubMed ID: 23984976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of two Gbetagamma-binding proteins--N-terminally truncated phosducin and beta-adrenergic receptor kinase C terminus (betaARKct)--in heart failure.
    Li Z; Laugwitz KL; Pinkernell K; Pragst I; Baumgartner C; Hoffmann E; Rosport K; Münch G; Moretti A; Humrich J; Lohse MJ; Ungerer M
    Gene Ther; 2003 Aug; 10(16):1354-61. PubMed ID: 12883532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure.
    Imai M; Rastogi S; Gupta RC; Mishra S; Sharov VG; Stanley WC; Mika Y; Rousso B; Burkhoff D; Ben-Haim S; Sabbah HN
    J Am Coll Cardiol; 2007 May; 49(21):2120-8. PubMed ID: 17531662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRK2 as a novel gene therapy target in heart failure.
    Rengo G; Lymperopoulos A; Leosco D; Koch WJ
    J Mol Cell Cardiol; 2011 May; 50(5):785-92. PubMed ID: 20800067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling.
    Rinaldi B; Donniacuo M; Sodano L; Gritti G; Martuscelli E; Orlandi A; Rafaniello C; Rossi F; Calzetta L; Capuano A; Matera MG
    Br J Pharmacol; 2015 Jul; 172(14):3627-37. PubMed ID: 25825265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure.
    Harding VB; Jones LR; Lefkowitz RJ; Koch WJ; Rockman HA
    Proc Natl Acad Sci U S A; 2001 May; 98(10):5809-14. PubMed ID: 11331748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction.
    Shah AS; White DC; Emani S; Kypson AP; Lilly RE; Wilson K; Glower DD; Lefkowitz RJ; Koch WJ
    Circulation; 2001 Mar; 103(9):1311-6. PubMed ID: 11238278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts.
    Williams ML; Hata JA; Schroder J; Rampersaud E; Petrofski J; Jakoi A; Milano CA; Koch WJ
    Circulation; 2004 Apr; 109(13):1590-3. PubMed ID: 15051637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor heart contractile dysfunction following prolonged ex vivo preservation can be prevented by gene-mediated beta-adrenergic signaling modulation.
    Tevaearai HT; Walton GB; Eckhart AD; Keys JR; Koch WJ
    Eur J Cardiothorac Surg; 2002 Nov; 22(5):733-7. PubMed ID: 12414039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenoviral beta-adrenergic receptor kinase inhibitor gene transfer improves exercise capacity, cardiac contractility, and systemic inflammation in a model of pressure overload hypertrophy.
    Gupta D; Molina EJ; Palma J; Gaughan JP; Long W; Macha M
    Cardiovasc Drugs Ther; 2008 Oct; 22(5):373-81. PubMed ID: 18690529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.